InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,540.78
(
0.58%
)
US TECH 100
19,769.60
(
0.65%
)
Dow Jones
39,212.36
(
-0.24%
)
Brent Oil
87.06
(
-0.31%
)
Bitcoin
55,516.77
(
-2.57%
)
Post# of 346050
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: jq1234 post# 150460

Thursday, 11/28/2013 2:18:45 AM

Thursday, November 28, 2013 2:18:45 AM

Post# of 346050
You missed the point. Accelerated Approval can be based on blood samples. The Pcr was mentioned as an example...as it was used for FDA approval with Roche via blood samples. You think 200-300% overall response rates provided by Bavi combos will not be something of interest? : )

Its more like who is not interested. PS is the target.....it will remain the target.

Happy Turkey Day JQ


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

Start posting your company's news
Only $200 per official company press release!